Depresivní onemocnění a ketamin
- Andrade, C. (2019). Oral ketamine for depression, 1: Pharmacologic considerations and clinical evidence. J Clin Psychiatry, 80(2). doi: 10.4088/JCP.19f12820
- Banov, M. D., Young, J. R., Dunn, T., & Szabo, S. T. (2019). Efficacy and safety of ketamine in the management of anxiety and anxiety spectrum disorders: A review of the literature. CNS Spectr, 1-12. doi: 10.1017/S1092852919001238
- Bell, R. F. (2012). Ketamine for chronic noncancer pain: Concerns regarding toxicity. Curr Opin Support Palliat Care, 6(2), 183-187. doi: 10.1097/SPC.0b013e328352812c
- Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000). Antidepressant effects of ketamine in depressed patients. Biol Psychiatry, 47(4), 351-354. doi: 10.1016/s0006-3223(99)00230-9
- Dakwar, E., Anerella, C., Hart, C. L., Levin, F. R., Mathew, S. J., & Nunes, E. V. (2014). Therapeutic infusions of ketamine: Do the psychoactive effects matter? Drug Alcohol Depend, 136, 153-157. doi: 10.1016/j.drugalcdep.2013.12.019
- Dakwar, E., Levin, F., Hart, C. L., Basaraba, C., Choi, J., Pavlicova, M., & Nunes, E. V. (2020). A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: A randomized midazolam-controlled pilot trial. Am J Psychiatry, 177(2), 125-133. doi: 10.1176/appi.ajp.2019.19070684
- Dakwar, E., Nunes, E. V., Hart, C. L., Foltin, R. W., Mathew, S. J., Carpenter, K. M., . . . Levin, F. R. (2019). A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: A randomized clinical trial. Am J Psychiatry, 176(11), 923-930. doi: 10.1176/appi.ajp.2019.18101123
- Dittrich, A. (1998). The standardized psychometric assessment of altered states of consciousness (ascs) in humans. Pharmacopsychiatry, 31 Suppl 2, 80-84. doi: 10.1055/s-2007-979351
- Dore, J., Turnipseed, B., Dwyer, S., Turnipseed, A., Andries, J., Ascani, G., . . . Wolfson, P. (2019). Ketamine assisted psychotherapy (kap): Patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy. J Psychoactive Drugs, 51(2), 189-198. doi: 10.1080/02791072.2019.1587556
- Gao, M., Rejaei, D., & Liu, H. (2016). Ketamine use in current clinical practice. Acta Pharmacol Sin, 37(7), 865-872. doi: 10.1038/aps.2016.5 Horacek, J., Brunovsky, M., Novak, T., Tislerova, B., Palenicek, T., Bubenikova-Valesova, V., . . . Hoschl, C. (2010). Subanesthetic dose of ketamine decreases prefrontal theta cordance in healthy volunteers: Implications for antidepressant effect. Psychol Med, 40(9), 1443-1451. doi: 10.1017/S0033291709991619
- Horacek, J., Lipski, M. , & Sos, P. (2016). Příběh jedné molekuly. Čtyři tváře ketaminu. Vesmír, 95(5), 272–275.
- Horacek, J., Palenicek, T., Malek, J., Scigel, V., Kurzova, A., & Hess, L. (2012). The influence of clonidine on oral ketamine-midazolam premedication in intellectually disabled patients indicated for dental procedures: Double-blind comparison of two sedation regimes. Neuro Endocrinol Lett, 33(4), 380-384.
- Iglewicz, A., Morrison, K., Nelesen, R. A., Zhan, T., Iglewicz, B., Fairman, N., . . . Irwin, S. A. (2015). Ketamine for the treatment of depression in patients receiving hospice care: A retrospective medical record review of thirty-one cases. Psychosomatics, 56(4), 329-337. doi: 10.1016/j.psym.2014.05.005
- Kishimoto, T., Chawla, J. M., Hagi, K., Zarate, C. A., Kane, J. M., Bauer, M., & Correll, C. U. (2016). Single-dose infusion ketamine and non-ketamine n-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: A meta-analysis of efficacy, safety and time trajectories. Psychol Med, 46(7), 1459-1472. doi: 10.1017/S0033291716000064
- Krupitsky, E., Burakov, A., Romanova, T., Dunaevsky, I., Strassman, R., & Grinenko, A. (2002). Ketamine psychotherapy for heroin addiction: Immediate effects and two-year follow-up. J Subst Abuse Treat, 23(4), 273-283. doi: 10.1016/s0740-5472(02)00275-1
- Krupitsky, E. M., Burakov, A. M., Dunaevsky, I. V., Romanova, T. N., Slavina, T. Y., & Grinenko, A. Y. (2007). Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence. J Psychoactive Drugs, 39(1), 13-19. doi: 10.1080/02791072.2007.10399860
- Liao, Y., Tang, J., Corlett, P. R., Wang, X., Yang, M., Chen, H., . . . Fletcher, P. C. (2011). Reduced dorsal prefrontal gray matter after chronic ketamine use. Biol Psychiatry, 69(1), 42-48. doi: 10.1016/j.biopsych.2010.08.030
- Liu, S. Y. W., Ng, S. K. K., Tam, Y. H., Yee, S. C. H., Lai, F. P. T., Hong, C. Y. L., . . . Ng, C. F. (2017). Clinical pattern and prevalence of upper gastrointestinal toxicity in patients abusing ketamine. J Dig Dis, 18(9), 504-510. doi: 10.1111/1751-2980.12512
- Luckenbaugh, D. A., Niciu, M. J., Ionescu, D. F., Nolan, N. M., Richards, E. M., Brutsche, N. E., . . . Zarate, C. A. (2014). Do the dissociative side effects of ketamine mediate its antidepressant effects? J Affect Disord, 159, 56-61. doi: 10.1016/j.jad.2014.02.017
- Morgan, C. J., Curran, H. V., & Independent Scientific Committee on, Drugs. (2012). Ketamine use: A review. Addiction, 107(1), 27-38. doi: 10.1111/j.1360-0443.2011.03576.x
- Muetzelfeldt, L., Kamboj, S. K., Rees, H., Taylor, J., Morgan, C. J., & Curran, H. V. (2008). Journey through the k-hole: Phenomenological aspects of ketamine use. Drug Alcohol Depend, 95(3), 219-229. doi: 10.1016/j.drugalcdep.2008.01.024
- Olney, J. W., Labruyere, J., & Price, M. T. (1989). Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science, 244(4910), 1360-1362. doi: 10.1126/science.2660263
- Olney, J. W., Labruyere, J., Wang, G., Wozniak, D. F., Price, M. T., & Sesma, M. A. (1991). Nmda antagonist neurotoxicity: Mechanism and prevention. Science, 254(5037), 1515-1518. doi: 10.1126/science.1835799
- Olney, J. W., Price, M. T., Fuller, T. A., Labruyere, J., Samson, L., Carpenter, M., & Mahan, K. (1986). The anti-excitotoxic effects of certain anesthetics, analgesics and sedative-hypnotics. Neurosci Lett, 68(1), 29-34. doi: 10.1016/0304-3940(86)90224-7
- Peltoniemi, M. A., Hagelberg, N. M., Olkkola, K. T., & Saari, T. I. (2016). Ketamine: A review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy. Clin Pharmacokinet, 55(9), 1059-1077. doi: 10.1007/s40262-016-0383-6
- Rosenblat, J. D., Carvalho, A. F., Li, M., Lee, Y., Subramanieapillai, M., & McIntyre, R. S. (2019). Oral ketamine for depression: A systematic review. J Clin Psychiatry, 80(3). doi: 10.4088/JCP.18r12475
- Shahani, R., Streutker, C., Dickson, B., & Stewart, R. J. (2007). Ketamine-associated ulcerative cystitis: A new clinical entity. Urology, 69(5), 810-812. doi: 10.1016/j.urology.2007.01.038
- Sos, P., Klirova, M., Novak, T., Kohutova, B., Horacek, J., & Palenicek, T. (2013). Relationship of ketamine’s antidepressant and psychotomimetic effects in unipolar depression. Neuro Endocrinol Lett, 34(4), 287-293.
- Vollenweider, F. X., & Kometer, M. (2010). The neurobiology of psychedelic drugs: Implications for the treatment of mood disorders. Nat Rev Neurosci, 11(9), 642-651. doi: 10.1038/nrn2884
- Wan, L. B., Levitch, C. F., Perez, A. M., Brallier, J. W., Iosifescu, D. V., Chang, L. C., . . . Murrough, J. W. (2015). Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry, 76(3), 247-252. doi: 10.4088/JCP.13m08852
- Xu, J., & Lei, H. (2014). Ketamine-an update on its clinical uses and abuses. CNS Neurosci Ther, 20(12), 1015-1020. doi: 10.1111/cns.12363